scholarly journals Prospective observational study in early breast cancer at University Hospital of Tlemcen

2017 ◽  
Vol 1 (2) ◽  
pp. 37-38
Author(s):  
I Lahfa- Merad ◽  
H Aris ◽  
S Chaibdraa Tani ◽  
N Hammou-Tani ◽  
S Saidi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Breast Cancer ◽  
Tumor Size ◽  
Ductal Carcinoma ◽  
Significant Proportion ◽  
Stage I ◽  
University Hospital ◽  
Stage Iii ◽  
Her2 Status ◽  
Study Population

Background: Breast cancer is the first cancer in women in Algeria. It affects a significant proportion of young women. Stage at diagnosis is made with a positive, massive, and often lymph node involvement. The objective of this study is to determine the clinicopathological and histological features of patients treated for invasive breast carcinoma. Methods: This is an observational prospective study from January 2006 to December 2011 done at the medical oncology department at the University Hospital Center of Tlemcen: 103 patients with early breast cancer were included. Results: Extreme age is between 29 and 70 years; 50% of patients are under 47 years. The average age at diagnosis of 46.45 ± 0.90 years; 54% are stage T2; 17% are stage T3 and 4% stage T4; stage III is the most frequent with 50.4%. Half of patients have four to nine nodes with relatively wide tumor size, and only one patient was stage I; 10% had more than 10 positive nodes. The infiltrating ductal carcinoma is the most common histological types (83.5%), followed by atypical carcinoma (5.82%). Note the predominance of grade II of Scarf Bloom and Richardson (58.25%), followed by grade III (36.89%) and grade I (1.91%). Over 50% of patients had a tumor size of 35.41 ± 1.82 mm. Hormone receptors were positive in 65% of patients (ER + PR +) and negative in 35%. HER2 status was determined in 82 patients, 12% expressed a positive score, and 67% of were negative. The luminal profile is the most common in our study population with 57.3%, followed by triple negative tumors or basal-like with 26.8%. Conservative surgical treatment was realized in 2.9% and an astectomy in most patients at 97%. Radiotherapy was performed in 83.5% of patients, and 65% of patients received hormone therapy according to hormone positivity. Conclusion: The clinical and histological profiles of the patients in our study population are different from Western populations by the average age of diagnosis of 46 years, 10 years higher for Western women, and the stage is more advanced for our population. The majority are at stage III, while Western women are diagnosed at stage I or II through screening. Given the Algerian profile, women should be offered screening at aged 40 years for earlier diagnosis and improved survival rate.

Triple-negative breast cancer: Epidemiology, characteristics, and survival in a Lebanese cohort

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e22228-e22228
Author(s):  
M. Ghosn ◽  
C. Hajj ◽  
F. Nasr ◽  
F. El Karak ◽  
G. Abadjian ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative ◽  
Ductal Carcinoma ◽  
Positive Family History ◽  
Disease Free Survival ◽  
Stage Iv ◽  
Stage I ◽  
Stage Ii ◽  
University Hospital ◽  
Stage Iii

e22228 Background: Breast cancer (BC) is the most common malignancy in women in Lebanon. Triple negative (TN) phenotype is known to be associated with an increased likelihood of recurrence and death. The purpose of this study is to determine the incidence, characteristics and survival of TN BC patients in a Medical Oncology department in a University Hospital in Lebanon. Methods: We retrospectively reviewed the pathology of all women with breast cancer that were seen in our institution between 1997 and 2008. TN BC patients (pts) were defined as those that were negative for all 3 receptors (estrogen, progesterone and HER2neu on immunohistochemistry). Pts' characteristics and survival of TN women were analyzed. Results: Of the 1599 breast cancer pts, 155 (9.7%) had a triple negative phenotype. Median age was 52 years. A positive family history of breast/ovarian cancer was found in 15 pts (10%). Pathology studies showed: invasive ductal carcinoma component in 138 pts (89%), pure medullary carcinoma in 7 pts (5%), pure invasive lobular carcinoma in 6 pts (4%), pure mucinous carcinoma in 3 pts (2%) and epidermoid carcinoma in 1 pt (1%). A grade III was found in 98 of specimens (63%). Twenty-six pts (17%) presented with stage I, 73 (47%) with stage II, 37 (24%) with stage III and 19 (12%) with stage IV. Twelve percent had inflammatory breast cancer. After a median follow up of 17 months (mths), 43 pts had relapsed (5 stage I, 18 stage II and 20 stage III). The most common sites of relapse were brain (in 20 % of cases), lungs (in 20% of cases) and bone (in 11% of cases). Five- year disease free survival and 5-year overall survival were respectively 75% and 88% for stage I, 58% and 72% for stage II and 40% and 63% for stage III. Adjuvant therapy was administered to 96% of pts among which a taxane-based regimen was used in 38% of cases . Median survival for stage IV was 19 mths with a first line taxane-based regimen used in 50% of cases. Conclusions: The incidence of TN BC in Lebanon is similar to that described in the literature. It has an aggressive course. Focus on understanding the biology of this particular BC subtype is essential for determining targets for future therapeutic options. No significant financial relationships to disclose.

Pathologic characteristics of breast cancer with special emphasis on prevalence of triple-negative breast cancer from Kenya: A 4-year experience.

2011 ◽  
Vol 29 (27_suppl) ◽  
pp. 35-35
Author(s):  
S. Sayed ◽  
Z. Moloo ◽  
S. Mukono ◽  
R. Wasike ◽  
R. R. Chauhan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Ductal Carcinoma ◽  
Significant Proportion ◽  
Small Sample ◽  
University Hospital ◽  
Breast Cancers ◽  
Grade 3

35 Background: Previous sub classification of breast cancer in Kenya has been fraught by small sample size, non uniform staining methodology and lack of independent review. Triple Negative Breast Cancer (TNBC) is a “special interest” cancer since it represents a significant proportion of breast cancer patients and is associated with a poorer prognosis. We aimed to determine the estrogen receptor (ER), progesterone receptor (PR) and Her2/neu receptor characteristics of breast cancers and the prevalence of TNBC diagnosed at Aga Khan University Hospital, Nairobi (AKUHN) between 2007 to date. Methods: Slides and blocks of archived invasive breast cancers diagnosed at AKUHN were identified, retrieved and reviewed by two independent pathologists. Histological type, grade and pathological stage were documented. Representative sections from available blocks were stained for ER, PR, Her2 with appropriate internal controls. Scores for ER/PR were interpreted based on the ALLRED system, Her2 /neu scoring followed CAP guidelines. The initial 111 cases were validated and confirmed at Sunnybrook Health Sciences Centre, Toronto. Results: 456 cases of invasive breast cancers were diagnosed at AKUHN during the study period. 91% of cases were invasive ductal carcinomas (NOS).The rest were special types. 37% of the tumors were grade 3 and 63% were grade 2. Blocks for 318 of 456 cases were available for receptor analysis. 54% were ER and/or PR positive, with 52% of these in women < 50 yrs. 86% of the ER and/or PR positive tumors were grade 2. Only 12% were Her2/neu positive. Of the 318 cases studied, 111 (32%) were identified as TNBC. Median age was 53 yrs. 88% were grade 3. Conclusions: Invasive ductal carcinoma (NOS) was the most common breast cancer in our study. Nearly half of our cases were ER and/or PR positive and a third were TNBC. Both occurred predominantly in women less than 50 yrs. This represents the largest validated pathologic sub classification of breast cancer from a tertiary academic hospital in Kenya. Expansion of this study to encompass all breast cancers diagnosed in Kenya is underway.

Association between standard clinical and pathological breast cancer characteristics and the 21-gene recurrence score: A population-based study

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 11002-11002
Author(s):  
I. Wolf ◽  
N. Ben-Baruch ◽  
R. Shapira-Frommer ◽  
S. Rizel ◽  
H. Goldberg ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Validation Study ◽  
Tumor Size ◽  
Ductal Carcinoma ◽  
Age Distribution ◽  
Recurrence Score ◽  
Population Based ◽  
Her2 Expression ◽  
Study Population ◽  
Risk Categories

11002 Background: The 21-gene recurrence score (RS) aims to quantify chemotherapy benefit in lymph node-negative, estrogen receptor (ER)-positive breast cancer (BC) patients. We aimed to elucidate the association between the RS and clinical-pathological features in a population-based Israeli cohort. Methods: Study population included all Israeli BC female patients referred to the RS assay from October 2004 until October 2006. Clinical and pathology data were collected upon referral, RS risk was categorized as previously defined (low < 18, intermediate 18–30, high = 31) and chemotherapy benefit was also assessed for each patient using NCCN guidelines, St. Gallen recommendations and Adjuvant! Online. Results: 300 patients were referred to the assay by 70 physicians from 16 institutions. Low, intermediate and high RS were noted in 109 (36 %), 134 (45 %) and 57 (19%) of the patients respectively, compared to 54%, 21% and 25% respectively, in the validation study (JCO;24:3726). Median age was 54 and median tumor size was 1.6 cm. Similar age distribution, tumor size and ER staining intensity were noted in all risk categories. Interestingly, no association has been identified between the RS and the presence of lymph nodes micrometastases. High tumor grade was noted in 15%, 20% and 56%; progesterone expression in 88% 72% 43%; non-infiltrative ductal carcinoma (IDC) 24%, 12% and 6%; and Her2 expression in 2%, 3% and 19% of the low, intermediate and high risk categories respectively (p<0.0001 for all variables). Risk assessment according to clinical guidelines or Adjuvant! Online correlated poorly with the RS. Conclusions: Risk stratification of referred Israeli patients differs from that of the validation study population. Moreover, the RS did not correlate with age, tumor size and ER intensity. The RS correlated with histology, grade, PR and Her2 expression and may be predicted, in specific subsets of patients, using these features. However, RS categorization cannot be predicted by commonly-used clinical predicting tools. No significant financial relationships to disclose.

Characteristics and behavior of HER-2/neu positive tumors in patients under 35 years of age with breast cancer

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e11634-e11634
Author(s):  
S. A. Vigo ◽  
M. Sansano ◽  
F. Marmissolle ◽  
A. Mainella ◽  
L. Lujan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tumor Size ◽  
Progressive Disease ◽  
Hormone Receptors ◽  
Ductal Carcinoma ◽  
Lung Metastases ◽  
Disease Free Survival ◽  
Her2 Status ◽  
Node Involvement ◽  
Her 2

e11634 Background: Breast cancer (BC) rarely occurs in young women. Presentation, behavior and prognosis of BC in such patients (pts), when compared with older women, are unclear. It is believed that tumor is more aggressive in biologic nature in this group of pts. Objective: to describe Her2/neu status, tumor behavior and prognosis in women aged 35 and under with BC. Methods: We reviewed the records of 45 women aged 35 years or less, with diagnosis of BC between 1999 and 2007. The original Her2 status was analyzed by immunohistochemistry (IHC) with a polyclonal antibody. The results were interpreted using score 0 to 3+. Fluorescence in situ hybridization (FISH) was performed in all samples. Results: Her2/neu overexpression showed up in 8 tumors (17.7%) and all of them were confirmed by FISH. In this group of pts (FISH positive) hormone receptors were positive in 50%. Stage at diagnosis was I 2 pts and II 6 pts. 5 out of the 8 pts with Her2/neu tumors had axillary node involvement (11.1% out of the total of population), and tumor size was more than 2cm at diagnosis. All of them were invasive ductal carcinoma. Postoperative radiotherapy was given to 6pts while all pts with Her2/neu positive tumors received chemotherapy with anthracyclines, taxanes and trastuzumab. Disease free survival of 24 month was achieved in 5pts, 1pt died with bone, lung and liver metastases. 2pts had progressive disease (bone and lung metastases one of them, and local recurrence the other one). Conclusions: In our population of pts, 17.7% were Her 2/neu positive. In this small group of pts lymph node involvement was frequent and tumor size was more than 2cm. Progressive disease with distant metastases in bone, lung and liver was observed. Despite of these negative characteristics 5 out of 8 pts (62.5%) had DFS of 2 years. No significant financial relationships to disclose.

Overall survival (OS) of men and women with breast cancer according to tumor subtype: A population-based study.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 1069-1069
Author(s):  
Julieta Leone ◽  
Ariel Osvaldo Zwenger ◽  
Bernardo Amadeo Leone ◽  
Carlos Teodoro Vallejo ◽  
Jose Pablo Leone
Keyword(s):  
Breast Cancer ◽  
Prognostic Significance ◽  
Growth Factor Receptor ◽  
Stage I ◽  
Stage Iii ◽  
Her2 Status ◽  
Tumor Subtype ◽  
Men And Women ◽  
Tumor Subtypes ◽  
Risk Of Death

1069 Background: The outcomes of male breast cancer (MBC) and female breast cancer (FBC) according to tumor subtype are poorly known. Our group previously reported the prognostic significance of tumor subtypes in MBC. The aim of this study was to analyze differences in OS between MBC and FBC according to tumor subtype compared with other factors. Methods: We evaluated men and women with microscopically confirmed invasive breast cancer between 2010 and 2013 with known estrogen receptor (ER) and progesterone receptor (PR) (together hormone receptor [HR]) status and human epidermal growth factor receptor 2 (HER2) status reported to the SEER program. Patients (pts) with other primary either before or after breast cancer were excluded. Pt characteristics were compared between MBC and FBC. Univariate and multivariate analyses were performed to determine the effect of each variable on OS. Results: We included 1,187 MBC and 166,054 FBC pts. Median age for MBC was 65 years (range 26-97) and for FBC was 60 years (range 18-108). Median follow-up was 21 months (range 1-48) for both groups. OS at 3 years for MBC and FBC was 85.6% and 90.4%, respectively (p = 0.0002). MBC pts were more frequently ductal, had higher grade, presented with more advanced stage and were more often HR+/HER2- (all p < 0.0001). MBC had worse OS than FBC in HR+/HER2- (Hazard ratio [HaR] 1.5; p = 0.0005), HR+/HER2+ (HaR 2.8; p < 0.0001) and triple negative (TN) (HaR 4.3; p < 0.0001) (p for interaction < 0.02). MBC had significantly worse OS than FBC in stage I and II, but similar OS in stage III and IV (p for interaction < 0.01). In multivariate analysis adjusted for age, race, grade, stage, surgery, radiation and marital status; HR+/HER2+ was the only subtype with significant differences in OS between MBC and FBC (HaR 2.0; p = 0.002). Conclusions: In this cohort, we observed significant differences in the distribution of tumor subtypes between MBC and FBC. OS was significantly different in both groups. Men had worse OS in stage I and II while similar OS in stage III and IV. There were significant differences in OS according to tumor subtype; compared with women, men with HR+/HER2+ tumors had twice the risk of death.

Ki67 as Proliferative Marker in Patients with Early Breast Cancer and Its Association with Clinicopathological Factors

Oncology ◽  
2021 ◽  
pp. 1-10
Author(s):  
Amelie de Gregorio ◽  
Thomas Wolfram Paul Friedl ◽  
Eva Hering ◽  
Peter Widschwendter ◽  
Nikolaus de Gregorio ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Breast Cancer ◽  
Tumor Biology ◽  
Growth Factor Receptor ◽  
University Hospital ◽  
Proliferation Index ◽  
Her2 Status ◽  
Clinicopathological Factors ◽  
Her2 Positive ◽  
Proliferative Marker

<b><i>Introduction:</i></b> Ki67 as a proliferative marker has prognostic and therapeutic relevance in early breast cancer (EBC). However, standard cutoffs for distinguishing low and high Ki67 do not exist. <b><i>Material and Methods:</i></b> Data from all patients treated at the University Hospital Ulm for EBC between January 2013 and December 2015 with documented results for internal Ki67 assessment of the primary (<i>n</i> = 917) tumor were retrospectively analyzed evaluating the associations between Ki67 and other clinicopathological factors. <b><i>Results:</i></b> 595 (64.9%) patients had a Ki67 &#x3c;20% and 322 (35.1%) a Ki67 ≥20%. The median Ki67 was 10% (range 1–90%). Median Ki67 values according to the hormone receptor (HR)/ human epidermal growth factor receptor 2 (HER2) subtypes were 10% for HR-positive/HER2 negative (HR+/HER2−) disease (<i>n</i> = 717), 20% for HR+/HER2+ (<i>n</i> = 76), 30% for HR−/HER2+ (<i>n</i> = 45), and 60% for HR−/HER2− (<i>n</i> = 75). 75.2% or 89.3% of all patients with HER2-positive or triple-negative disease had a Ki67 ≥20%, respectively. Using a multivariable logistic regression with Ki67 (&#x3c;20% vs. ≥20%) as binary dependent variable, younger age, positive nodal status, higher grading, histological nonspecific type carcinoma, negative HR status, and positive HER2 status were shown to be significantly associated with a higher proliferative index (Ki67 ≥20%). <b><i>Conclusion:</i></b> This analysis described Ki67 in different subtypes in EBC and its association with clinicopathological factors. According to more aggressive tumor biology, the respective subgroups also showed higher median Ki67 levels. However, definition of low and high proliferation index itself is difficult. It is essential to interpret Ki67 indices carefully with regard to the own institutional values and other clinicopathological factors.

Comparison of Mammography and Ultrasonography for Tumor Size of DCIS of Breast Cancer

2019 ◽  
Vol 15 (2) ◽  
pp. 209-213
Author(s):  
Yu Wang ◽  
Jiantao Wang ◽  
Haiping Wang ◽  
Xinyu Yang ◽  
Liming Chang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Correlation Coefficient ◽  
Tumor Size ◽  
Ductal Carcinoma ◽  
Pearson Correlation ◽  
Dense Breast ◽  
Pathological Examination ◽  
Negative Group ◽  
The Difference

Objective: Accurate assessment of breast tumor size preoperatively is important for the initial decision-making in surgical approach. Therefore, we aimed to compare efficacy of mammography and ultrasonography in ductal carcinoma in situ (DCIS) of breast cancer. Methods: Preoperative mammography and ultrasonography were performed on 104 women with DCIS of breast cancer. We compared the accuracy of each of the imaging modalities with pathological size by Pearson correlation. For each modality, it was considered concordant if the difference between imaging assessment and pathological measurement is less than 0.5cm. Results: At pathological examination tumor size ranged from 0.4cm to 7.2cm in largest diameter. For mammographically determined size versus pathological size, correlation coefficient of r was 0.786 and for ultrasonography it was 0.651. Grouped by breast composition, in almost entirely fatty and scattered areas of fibroglandular dense breast, correlation coefficient of r was 0.790 for mammography and 0.678 for ultrasonography; in heterogeneously dense and extremely dense breast, correlation coefficient of r was 0.770 for mammography and 0.548 for ultrasonography. In microcalcification positive group, coeffient of r was 0.772 for mammography and 0.570 for ultrasonography. In microcalcification negative group, coeffient of r was 0.806 for mammography and 0.783 for ultrasonography. Conclusion: Mammography was more accurate than ultrasonography in measuring the largest cancer diameter in DCIS of breast cancer. The correlation coefficient improved in the group of almost entirely fatty/ scattered areas of fibroglandular dense breast or in microcalcification negative group.

Identification of biomarkers and functional modules from genomic data in stage-wise breast cancer

2020 ◽  
Vol 15 ◽  
Author(s):  
Athira K ◽  
Vrinda C ◽  
Sunil Kumar P V ◽  
Gopakumar G
Keyword(s):  
Breast Cancer ◽  
Expression Patterns ◽  
Differential Expression Analysis ◽  
Predictive Biomarkers ◽  
Stage I ◽  
Stage Ii ◽  
Stage Iii ◽  
Functional Modules ◽  
Incidence And Mortality ◽  
Multiple Stages

Background: Breast cancer is the most common cancer in women across the world, with high incidence and mortality rates. Being a heterogeneous disease, gene expression profiling based analysis plays a significant role in understanding breast cancer. Since expression patterns of patients belonging to the same stage of breast cancer vary considerably, an integrated stage-wise analysis involving multiple samples is expected to give more comprehensive results and understanding of breast cancer. Objective: The objective of this study is to detect functionally significant modules from gene co-expression network of cancerous tissues and to extract prognostic genes related to multiple stages of breast cancer. Methods: To achieve this, a multiplex framework is modelled to map the multiple stages of breast cancer, which is followed by a modularity optimization method to identify functional modules from it. These functional modules are found to enrich many Gene Ontology terms significantly that are associated with cancer. Result and Discussion: predictive biomarkers are identified based on differential expression analysis of multiple stages of breast cancer. Conclusion: Our analysis identified 13 stage-I specific genes, 12 stage-II specific genes, and 42 stage-III specific genes that are significantly regulated and could be promising targets of breast cancer therapy. That apart, we could identify 29, 18 and 26 lncRNAs specific to stage I, stage II and stage III respectively.

scholarly journals Recommendation and Acceptance of Counselling for Familial Cancer Risk in Newly Diagnosed Breast Cancer Cases

Breast Care ◽  
2021 ◽  
pp. 1-6
Author(s):  
Karin Kast ◽  
Julia Häfner ◽  
Evelin Schröck ◽  
Arne Jahn ◽  
Carmen Werner ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Risk ◽  
Genetic Counselling ◽  
Primary Breast Cancer ◽  
Ductal Carcinoma ◽  
Familial Cancer ◽  
University Hospital ◽  
Tumor Board ◽  
Newly Diagnosed ◽  
Familial Cancer Risk

<b><i>Background:</i></b> In clinical routine, not every patient who is offered genetic counselling and diagnostics in order to investigate a familial cancer risk predisposition opts for it. Little is known about acceptance of counselling and testing in newly diagnosed breast cancer cases in Germany. <b><i>Methods:</i></b> All primary breast cancer cases and patients with DCIS (ductal carcinoma in situ) treated at the University Hospital of Dresden between 2016 and 2019 were included. The number of tumor board recommendations for genetic counselling on the basis of the GC-HBOC risk criteria was recorded. Acceptance was analyzed by number of cases with counselling in the GC-HBOC-Center Dresden. <b><i>Results:</i></b> Of 996 primary breast cancer and DCIS cases, 262 (26.3%) were eligible for genetic counselling. Recommendation for genetic counselling was accepted by 64.1% (168/262). Of these 90.5% (152/168) opted for molecular genetic analysis. The acceptance rate for counselling increased between 2016 and 2019 from 58.3 to 72.6%. Altogether, 20.4% (31/152) patients were found to carry a pathogenic variant in the breast cancer genes <i>BRCA1</i> or <i>BRCA2</i>. <b><i>Conclusion:</i></b> Acceptance of recommendation is increasing as clinical consequences augment. Optimization in providing information about hereditary cancer risk and in accessibility of counselling and testing is required to further improve acceptance of recommendation.

Sign in / Sign up

Export Citation Format

Share Document